Biorestorative Therapies, Inc. (NASDAQ:BRTX) Sees Significant Decline in Short Interest

Biorestorative Therapies, Inc. (NASDAQ:BRTX) was the target of a significant drop in short interest in July. As of July 31st, there was short interest totaling 463,966 shares, a drop of 39.9% from the July 15th total of 772,008 shares. Based on an average daily trading volume, of 430,028 shares, the days-to-cover ratio is presently 1.1 days. Currently, 2.1% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biorestorative Therapies in a research report on Wednesday, May 27th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Biorestorative Therapies presently has an average rating of “Sell”.

Biorestorative Therapies Stock Up 6.1%

Shares of Biorestorative Therapies stock traded up $0.01 on Wednesday, hitting $0.23. 119,013 shares of the company’s stock traded hands, compared to its average volume of 7,874,835. Biorestorative Therapies has a 52-week low of $0.16 and a 52-week high of $1.89. The stock has a market cap of $5.76 million, a P/E ratio of -0.21 and a beta of 0.79. The firm’s 50-day moving average is $0.32 and its 200 day moving average is $0.33.

Institutional Trading of Biorestorative Therapies

Several hedge funds and other institutional investors have recently bought and sold shares of BRTX. Virtu Financial LLC grew its position in shares of Biorestorative Therapies by 102.4% in the 3rd quarter. Virtu Financial LLC now owns 24,351 shares of the company’s stock worth $35,000 after acquiring an additional 12,319 shares in the last quarter. DRW Securities LLC bought a new stake in Biorestorative Therapies during the fourth quarter valued at $55,000. Finally, Citadel Advisors LLC acquired a new stake in shares of Biorestorative Therapies during the third quarter worth $152,000. 69.38% of the stock is owned by institutional investors.

Biorestorative Therapies Company Profile

Biorestorative Therapies Inc (NASDAQ: BRTX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of regenerative tissue therapy products. The company leverages a proprietary universal allogeneic cell technology platform to create high-potency cell therapy candidates designed to promote tissue repair, reduce inflammation and accelerate healing in areas damaged by disease or medical treatment.

Its lead development program targets radiation-induced oral mucositis (RIOM), a painful and dose-limiting side effect experienced by head and neck cancer patients undergoing radiotherapy.